Abstract:Rheumatoid arthritis (RA) is an autoimmune disease accompanied with serious symptoms, such as joint destruction and chronic synovitis. Though many anti-RA drugs could improve the outcome of RA patients to a certain extent, about 40% inefficient rate, severe side effects, and high costs have become urgent problems. Therefore, exploring new alternative drugs for RA therapy is still an urgent need so far. Isatin is an important structural motif found in numerous biologically active compounds and therapeutic agents. Herein, we aim to synthesize several novel isatin analogues for RA therapy and further explore the mechanism of the most potential anti-RA drug candidate in suppressing the pathological progress of RA in vitro and in vivo. We found that the most therapeutic potential compound, a novel small molecule isatin-honokiol hybrid named CT5-2 inhibited the viability of RA-fibroblast-like synoviocytes (FLSs), an effector cell of synovial hyperplasia in the RA synovial tissue with IC50 ranging from 8.54 to 10.66 mu M. In addition, CT5-2 reduced the DNA replication and triggered cell cycle arrest and apoptosis of RA-FLSs. Moreover, differential analyses of RNA-sequencing and the mechanistic studies demonstrated that CDCA7 is a key gene correlated with RA progression, and CT5-2 could inhibit the c-Myc/CDCA7/p65 pathway to regulate CDK1, Bcl-2, and vimentin in RA-FLSs. Furthermore, CT5-2 relieved collagen-induced arthritis (CIA) and reduced the level of CDCA7, CDK1, Bcl-2, and vimentin of synovial tissue in CIA mice. Taken together, the novel small molecule isatin-honokiol hybrid CT5-2 exhibits a potential anti-RA drug candidate that inhibits proliferation and triggers cell cycle arrest and apoptosis of RA-FLSs by regulating the c-Myc/CDCA7/p65 pathway. Our study lays a good foundation for further clinical research and structural modification of CT5-2.

Design and Synthesis of Novel Double-Ring Conjugated Enones as Potent Anti-rheumatoid Arthritis Agents

Design, synthesis and anti-rheumatoid arthritis evaluation of double-ring conjugated enones

Design, synthesis and anti-rheumatoid arthritis activity of target TLR4 inhibitors

Synthesis, activity and mechanism for double-ring conjugated enones

Novel Isatin-Based Hybrids As Potential Anti-Rheumatoid Arthritis Drug Candidates: Synthesis and Biological Evaluation

Synthesis and Anti-Rheumatoid Arthritis Activities of 3-(4-aminophenyl)-coumarin Derivatives

Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis

Synthesis and biological evaluation of novel sinomenine derivatives as anti-inflammatory agents.

Design, Synthesis, and Antirheumatoid Arthritis Mechanism of TLR4 Inhibitors

Synthesis and Biological Activities of Chemical Drugs for the Treatment of Rheumatoid Arthritis

Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs–CAIs) for the treatment of rheumatoid arthritis

Discovery of Cyclic Peptide Inhibitors Targeted on TNFα-TNFR1 from Computational Design and Bioactivity Verification

Anti-inflammation and joint lubrication dual effects of a novel hyaluronic acid/curcumin nanomicelle improve the efficacy of rheumatoid arthritis therapy.

Rational Design of Benzylidenehydrazinyl-Substituted Thiazole Derivatives As Potent Inhibitors of Human Dihydroorotate Dehydrogenase with in Vivo Anti-arthritic Activity.

Design, synthesis, and characterization of rhein analogs as novel inhibitors of scavenger receptor A

Synthesis and in vitro and in vivo anti-inflammatory activity of novel 4-ferrocenylchroman-2-one derivatives.

Akuammiline alkaloid derivatives: divergent synthesis and effect on the proliferation of rheumatoid arthritis fibroblast-like synoviocytes

Synthesis and Anti-inflammatory Evaluation of Novel 1,2,3-Triazole Derivatives

Structure-Based Drug Design and Synthesis of Pyrrolidine-2,5-diones as Novel TNF-α Inhibitors

Clinically approved small-molecule drugs for the treatment of rheumatoid arthritis

Transformable peptide blocks NF-κB/IκBα pathway through targeted coating IκBα against rheumatoid arthritis